Edition:
United Kingdom

People: VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

0.99USD
22 May 2018
Change (% chg)

$-0.02 (-1.95%)
Prev Close
$1.01
Open
$1.02
Day's High
$1.02
Day's Low
$0.99
Volume
9,456
Avg. Vol
92,326
52-wk High
$2.65
52-wk Low
$0.69

Singh, Shawn 

Mr. Shawn K. Singh, J.D., is the Chief Executive Officer, Director of Vistagen Therapeutics, Inc. has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000 and served on our management team (part-time) from late-2003, following our acquisition of Artemis Neuroscience, of which he was President, to August 2009. Mr. Singh has over 20 years of experience working with biotechnology, medical device and pharmaceutical companies, both private and public. From February 2001 to August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer and General Counsel of Cato Research, a profitable global contract research organization (CRO) affiliated with Cato BioVentures. Mr. Singh served as President (part-time) of Echo Therapeutics (NASDAQ: ECTE), a medical device company, from September 2007 to June 2009, and as a member of its Board of Directors from September 2007 through December 2011. He also served as Chief Executive Officer (part-time) of Hemodynamic Therapeutics, a private biopharmaceutical company affiliated with Cato BioVentures, from November 2004 to August 2009. From late-2000 to February 2001, Mr. Singh served as Managing Director of Start-Up Law, a management consulting firm serving biotechnology companies. Mr. Singh also served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular disorders, from late-1993 to late-2000, and as a corporate finance associate of Morrison & Foerster LLP, an international law firm, from 1991 to late-1993. Mr. Singh currently serves as a member of the Board of Directors of Armour Therapeutics, a private biotechnology company focused on prostate cancer.

Basic Compensation

Total Annual Compensation, USD 347,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 688,050
Fiscal Year Total, USD 1,035,550

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

H. Snodgrass

763,700

Shawn Singh

1,035,550

Jerrold Dotson

479,350

Mark Smith

--

Jerry Gin

--

Jon Saxe

--
As Of  31 Mar 2015